5PSQ-116 Persistence of inhibitors of interleukin-23 (anti-IL-23) for the treatment of moderate-to-severe psoriasis (msPs) in the routine clinical practice conditions
| Autor: | L Domínguez Senín, S Camacho Parreño, E Sánchez Gómez, M Rodriguez Jorge, MD Santos-Rubio |
|---|---|
| Rok vydání: | 2023 |
| Zdroj: | Section 5: Patient safety and quality assurance. |
| DOI: | 10.1136/ejhpharm-2023-eahp.314 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|